In vitro -- undersøgelser har vist, at rosiglitazon primært metaboliseres af CYP2C8, med CYP2C9 som en mindre metaboliseringsvej.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with CYP2C9 as only a minor pathway.